Future of Generic Semaglutide The patent protection for most semaglutide formulations will begin expiring in the early 2030s in the United States
During pregnancy, DAO concentrations in the body may increase by as much as 500%, due to the production of DAO by the placenta (ref), which may well explain the reduction in food intolerances women experience during this period (ref)
[1] Liraglutide can be prescribed for the treatment of obesity in adults with a body mass index (BMI) of 30 or higher, or a BMI of over 27 if they have at least one other weight related health condition (such as adults with type 2 diabetes, high cholesterol, high blood pressure, prediabetes, or obstructive sleep apnoea)
Meaning they are both extremely important for our bodies, almost like joint gold medal winners
Food and Drug Administration, the European Medicines Agency, or any comparable regulator for the treatment, cure, or prevention of obesity, type 2 diabetes, or any other disease